Plasma/Serum Plasmalogens. Methods of Analysis and Clinical Significance.

Advances in Clinical Chemistry

Volumn 70, Issue , 2015, Pages 31-94

  Maeba, Ryouta ^a   Nishimukai, Megumi ^b,e   Sakasegawa, Shin Ichi ^c   Sugimori, Daisuke ^d   Hara, Hiroshi ^e  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b IWATE UNIVERSITY   (Japan)

^c ASAHI KASEI PHARMA CORPORATION   (Japan)

^d FUKUSHIMA UNIVERSITY   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Biomarker; Coronary artery disease; Dementia; Ether glycerophospholipid; Liquid chromatography tandem mass spectrometry; Peroxisome; Plasmalogen

Indexed keywords

PLASMALOGEN;

ADULT; AGED; ATHEROSCLEROSIS; BLOOD; CORONARY ARTERY DISEASE; DEMENTIA; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; CHROMATOGRAPHY, LIQUID; CORONARY ARTERY DISEASE; DEMENTIA; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PLASMALOGENS; YOUNG ADULT;

EID: 84952718340     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2015.03.005     Document Type: Chapter

References (65)

1. Chung H.Y., Lee E.K., Choi Y.J., Kim J.M., Kim D.H., Zou Y., et al. Molecular inflammation as an underlying mechanism of the aging process and age-related diseases. J. Dent. Res. 2011, 90:830-840.
2. Nordgren M., Fransen M. Peroxisomal metabolism and oxidative stress. Biochimie 2014, 98:56-62.
3. Jacob K.D., Noren Hooten N., Trzeciak A.R., Evans M.K. Markers of oxidant stress that are clinically relevant in aging and age-related disease. Mech. Ageing Dev. 2013, 134:139-157.
4. Horrocks L.A., Sharma M. Plasmalogens and O-alkyl glycerophospholipids. Phospholipids 1982, 51-93. Elsevier Biomedical Press, Amsterdam. L.A. Hawthorme, G.B. Ansell (Eds.).
5. Maeba R., Hara H. Serum choline plasmalogen is a reliable biomarker for atherogenic status. Coronary artery disease: new insights and novel approaches 2012, 243-260. InTech, Croatia. A. Aqueri (Ed.).
6. Wanders R.J.A., Waterham H.R. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim. Biophys. Acta 2006, 1763:1707-1720.
7. Honsho M., Asaoku S., Fujiki Y. Posttranslational regulation of fatty acyl-CoA reductase 1, Far1, controls ether glycerophospholipid synthesis. J. Biol. Chem. 2010, 285:8537-8542.
8. Honsho M., Asaoku S., Fukumoto K., Fujiki Y. Topogenesis and homeostasis of fatty acyl-CoA reductase 1. J. Biol. Chem. 2013, 288:34588-34598.
9. Buchert R., Tawamie H., Smith C., Uebe S., Innes A.M., Al Hallak B., et al. A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. Am. J. Hum. Genet. 2014, 95:602-610.
10. Lee T.C. Biosynthesis and possible biological functions of plasmalogens. Biochim. Biophys. Acta 1998, 1394:129-145.
11. Watschinger K., Werner E.R. Orphan enzymes in ether lipid metabolism. Biochimie 2013, 95:59-65.
12. Farooqui A.A., Horrocks L.A. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 2001, 7:232-245.
13. da Silva T.F., Sousa V.F., Malheiro A.R., Brites P. The importance of ether-phospholipids: a view from the perspective of mouse models. Biochim. Biophys. Acta 2012, 1822:1501-1508.
14. Nagan N., Zoeller R.A. Plasmalogens: biosynthesis and functions. Prog. Lipid Res. 2001, 40:199-229.
15. Han X., Holtzman D.M., McKeel D.W. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 2001, 77:1168-1180.
16. Lohner K., Balgavy P., Hermetter A., Paltauf F., Laggner P. Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogen. Biochim. Biophys. Acta 1991, 1061:132-140.
17. Glaser P.E., Gross R.W. Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adapt an HII phase with its ability to promote membrane fusion. Biochemistry 1994, 33:5805-5812.
18. Wallner S., Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem. Phys. Lipids 2011, 164:573-589.
19. Lessig J., Fuchs B. Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr. Med. Chem. 2009, 16:2021-2041.
20. Zoeller R.A., Lake A.C., Nagan N., Gaposchkin D.P., Legner M.A., Lieberthal W. Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of vinyl ether. Biochem. J. 1999, 338:769-776.
21. Hahnel D., Thiery J., Brosche T., Engelmann B. Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2431-2438.
22. Maeba R., Ueta N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res. 2003, 44:164-171.
23. Braverman N.E., Moser A.B. Functions of plasmalogen lipids in health and disease. Biochim. Biophys. Acta 2012, 1822:1442-1452.
24. Vance J.E. Lipoproteins secreted by cultured rat hepatocytescontain the antioxidant 1-alk-1-enyl-2-acylglycerophosphoethanolamine. Biochim. Biophys. Acta 1990, 1045:128-134.
25. Wiesner P., Leidl K., Boettcher A., Schmitz G., Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 2009, 50:574-585.
26. Poynter M.E., Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 1998, 273:32833-32841.
27. Ingrand S.S., Wahl A., Favreliere S., Barbot F., Tallineau C. Quantification of long-chain aldehydes by gas chromatography coupled to mass spectrometry as a tool for simultaneous measurement of plasmalogens and their aldehydic breakdown products. Anal. Biochem. 2000, 280:65-72.
28. Horrocks L.A. The alk-1-enyl group content of mammalian myelin phosphoglycerides by quantitative two-dimensional thin-layer chromatography. J. Lipid Res. 1968, 9:469-472.
29. Williams J.N., Anderson C.E., Jasik A.D. A sensitive and specific method for plasmalogens and other enol ethers. J. Lipid Res. 1962, 3:378-381.
30. Gottfried E.L., Rapport M.M. The biochemistry of plasmalogens. J. Biol. Chem. 1962, 237:329-333.
31. -). Anal. Biochem. 2004, 331:169-176.
32. Maeba R., Yamazaki Y., Nezu T., Okazaki T. Improvement and validation of 125I-high-performance liquid chromatography method for determination of total human serum choline and ethanolamine plasmalogens. Ann. Clin. Biochem. 2012, 49:86-93.
33. Murakami-Murofushi K., Uchiyama A., Fujiwara Y., Kobayashi T., Kobayashi S., Mukai M., et al. Biological functions of a novel lipid mediator, cyclic phosphatidic acid. Biochim. Biophys. Acta 2002, 1582:1-7.
34. Bligh E.G., Dyer W.J. A rapid method of total extraction and purification. Can. J. Biochem. Physiol. 1959, 31:911-947.
35. Zemski Berry K.A., Murphy R.C. Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids. J. Am. Soc. Mass Spectrom. 2004, 15:1499-1508.
36. Shoji N., Nakagawa K., Asai A., Fujita I., Hashiura A., Nakajima Y., et al. LC-MS/MS analysis of carboxymethylated and carboxyethylated phosphatidylethanolamines in human erythrocytes and blood plasma. J. Lipid Res. 2010, 51:2445-2453.
37. Zhao Y.Y., Xiong Y., Curtis J.M. Measurement of phospholipids by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry: the determination of choline containing compounds in foods. J. Chromatogr. A 2011, 1218:5470-5479.
38. Nishimukai M., Yamashita M., Watanabe Y., Yamazaki Y., Nezu T., Maeba R., et al. Lymphatic absorption of choline plasmalogen is much higher than that of ethanolamine plasmalogen in rats. Eur. J. Nutr. 2011, 50:427-436.
39. Hui S.P., Chiba H., Kurosawa T. Liquid chromatography-mass spectrometric determination of plasmalogens in human plasma. Anal. Bioanal. Chem. 2011, 400:1923-1931.
40. Norris C., Fong B., MacGibbon A., McJarrow P. Analysis of phospholipids in rat brain using liquid chromatography-mass spectrometry. Lipids 2009, 44:1047-1054.
41. Nishimukai M., Maeba R., Yamazaki Y., Nezu T., Sakurai T., Takahashi Y., et al. Serum choline plasmalogens, particularly those with oleic acid in sn-2, are associated with proatherogenic state. J. Lipid Res. 2014, 55:956-965.
42. 1 from Streptomyces albidoflavus NA297. FEBS Open Bio 2012, 28:318-327.
43. 1 from Streptomyces albidoflavus NA297. J. Struct. Biol. 2013, 182:192-196.
44. Ota H., Tamezane H., Sasano Y., Hokazono E., Yasuda Y., Sakasegawa S., et al. Enzymatic characterization of an amine oxidase from Arthrobacter sp. used to measure phosphatidylethanolamine. Biosci. Biotechnol. Biochem. 2008, 72:2732-2738.
45. Ikuta S., Imamura S., Misaki H., Horiuti Y. Purification and characterization of choline oxidase from Arthrobacter globiformis. J. Biochem. 1977, 82:1741-1749.
46. 2 isoforms. Activation by physiologic concentrations of calcium ion. J. Biol. Chem. 1986, 261:10467-10470.
47. 2. A calcium-independent phospholipase with absolute sn-2 regiospecificity for diradyl glycerophospholipids. J. Biol. Chem. 1990, 265:10622-10630.
48. 2 in cytosol of small intestinal epithelium. Biochim. Biophys. Acta 1999, 1437:142-156.
49. Wu L.C., Pfeiffer D.R., Calhoon E.A., Madiai F., Marcucci G., Liu S., et al. Purification, identification, and cloning of lysoplasmalogenase, the enzyme that catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogen. J. Biol. Chem. 2011, 286:24916-24930.
50. Brites P., Waterham H.R., Wanders R.J.A. Functions and biosynthesis of plasmalogen in health and disease. Biochem. Biophys. Acta 2004, 1636:219-231.
51. Colas R., Sassolas A., Guichardant M., Cugnet-Anceau C., Moret M., Moulin P., et al. LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia 2011, 54:2931-2940.
52. Stenvinkel P., Diczfalusy U., Lindholm B., Heimbürger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol. Dial. Transplant. 2004, 19:972-976.
53. Graessler J., Schwudke D., Schwarz P.E., Herzog R., Shevchenko A., Bornstein S.R. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 2009, 4:e6261.
54. Pietiläinen K.H., Sysi-Aho M., Rissanen A., Seppänen-Laakso T., Yki-Järvinen H., Kaprio J., et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS One 2007, 2:e218.
55. Maeba R., Maeda T., Kinoshita M., Takao K., Takenaka H., Kusano J., et al. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J. Atheroscler. Thromb. 2007, 14:12-18.
56. Demopoulos C., Karantonis H., Antonopoulou S. Platelet activating factor-a molecular link between atherosclerosis theories. Eur. J. Lipid Sci. Technol. 2003, 105:705-716.
57. Thukkani A.K., Martinson B.D., Albert C.J., Vogler G.A., Ford D.A. Neutrophil-mediated accumulation of 2-ClHDA during myocardial infarction: 2-ClHDA-mediated myocardial injury. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H2955-H2964.
58. Thukkani A.K., McHowat J., Hsu F.F., Brennan M.L., Hazen S.L., Ford D.A. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 2003, 108:3128-3133.
59. Nishimukai M., Maeba R., Ikuta A., Asakawa N., Kamiya K., Yamada S., et al. Serum choline plasmalogens-those with oleic acid in sn-2-are biomarkers for coronary artery disease. Clin. Chim. Acta 2014, 437C:147-154.
60. Goodenowe D.B., Cook L.L., Liu J., Lu Y., Jayasinghe D.A., Ahiahonu P.W., et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 2007, 48:2485-2498.
61. Wood P.L., Mankidy R., Ritchie S., Heath D., Wood J.A., Flax J., et al. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J. Psychiatry Neurosci. 2010, 35:59-62.
62. Katoh S., Shimogaki H., Onodera A., et al. Development of the revised version of Hasegawa's Dementia Scale (HDS-R) (in Japanese). Jpn. J. Geriatr. Psychiatry 1991, 2:1339-1347.
63. Folstein M., Folstein S., McHugh P. "Mini-mental state"-a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
64. Fujiwara Y., Suzuki H., Yasunaga M., Sugiyama M., Ijuin M., Sakuma N., et al. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr. Gerontol. Int. 2010, 10:225-232.
65. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.